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evaluate sildenafil’s activity in PBMCs from patients with 
elevated OPN levels.
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Introduction
Osteopontin (OPN) is a member of the small integrin-bind-
ing ligand N-linked glycoprotein family proteins (Fisher 
et al. 2001; Ramaiah and Rittling 2008; Rangaswami et al. 
2006). OPN is expressed by a wide variety of cell types 
such as bone cells, neurons, epithelial cells, pericytes, fibro-
blasts, hepatocytes, tubular cells, vascular smooth muscle 
cells and immune system cells [T and B cells, natural killer 
(NK) cells, NK T cells, dendritic cells, macrophages, neu-
trophils] (Denhardt and Noda 1998; Ramaiah and Rittling 
2008; Uede 2011). OPN is a pleiotropic protein which is 
involved in physiological tissue remodeling processes 
[angiogenesis, bone formation and resorption, wound 
healing (Sodek et  al. 2000)]. Moreover, OPN has been 
implicated in the development of a number of pathologi-
cal conditions, such as cancer (Afify et al. 2009; Ramaiah 
and Rittling 2008), autoimmune disorders, infections (Glas 
et  al. 2011; Mishima et  al. 2007), asthma (Cantor 1995; 
Carecchio and Comi 2011; Frenzel and Weiss 2011; Har-
ris and Sadiq 2009; Konno et al. 2011; Murugaiyan et al. 
2008; Zandman-Goddard and; Shoenfeld 2003), cardio-
vascular diseases (Singh et al. 2007), as well as kidney and 
liver diseases (Cao et al. 2012; Ramaiah and Rittling 2008).
OPN regulates cellular immunity, including innate and 
adaptive components. OPN stimulates antibodies produc-
tion by B cells, regulates macrophages migration, activa-
tion, capacity for phagocytosis and nitric oxide production 
Abstract The aim of this study was to investigate the 
ability of sildenafil to regulate osteopontin (OPN) gene and 
protein in peripheral blood mononuclear cells (PBMCs) 
from healthy blood donors. OPN is expressed by a wide 
variety of cell types, including immune cells. OPN func-
tions are linked to various physiological and pathological 
conditions. Sildenafil is a selective inhibitor of type 5 phos-
phodiesterase. Sildenafil has recently been found to have 
immunomodulatory effects in animal models and in stud-
ies performed in humans. PMA-stimulated and unstimu-
lated PBMCs from 16 healthy blood donors (men) were 
cultured with sildenafil (at concentrations of 400 ng/ml and 
4 µg/ml). OPN level in culture supernatants was measured 
by enzyme-linked immunosorbent assay. The analysis of 
OPN gene expression was performed by real-time PCR. 
Cell viability was assessed by trypan blue staining. PMA 
plus ionomycin stimulation of PBMCs resulted in a sig-
nificant increase of OPN production and gene expression 
(p < 0.001). Sildenafil significantly decreased OPN secre-
tion (p < 0.05) and gene expression (p < 0.05) in stimulated 
PBMCs; however, had no effect on OPN in unstimulated 
PBMCs. Sildenafil did not affect PBMCs viability. Silde-
nafil downregulates OPN in PBMCs from healthy men. 
Despite accumulating evidence for the immunomodulatory 
effects of sildenafil on human immune system cells, further 
studies are needed to determine if this drug affects the level 
of cGMP and NF-κB in PBMCs. In addition, it is needed to 
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and enhances interleukin (IL)-17-producing T helper (Th) 
17 cell responses. In addition, OPN induces dendritic cells 
maturation, promotes activation of T cells, and can enhance 
the Th1-mediated inflammatory process (Ashkar et  al. 
2000; Brown 2012; Denhardt and Guo 1993; Murugaiyan 
et  al. 2008; Shinohara et  al. 2006; Wang and Denhardt 
2008). Moreover, OPN regulates immune suppression, cell 
adhesion and chemotaxis (Wai and Kuo 2004). These func-
tions are important for the pathological function of OPN.
It is quite a recent finding that some inflammatory pro-
cesses can be counteracted by phosphodiesterase type 5 
(PDE5) inhibitors (Pifarré et al. 2014). Sildenafil is a selec-
tive inhibitor of PDE5. PDE5 is a critical component in the 
cGMP-PKG signaling pathway. cGMP plays an important 
role in the regulation of activity of a number of cell popula-
tions, including inflammatory and immune cells (Chrysant 
and Chrysant 2012; Szczypka et al. 2012).
At the present time, sildenafil and other inhibitors of 
PDE5 have Federal Drug Administration approval for 
the treatment of erectile dysfunction (ED) and pulmo-
nary artery hypertension (Boswell-Smith et  al. 2006) but 
researchers are still looking for new therapeutic indications 
for these drugs.
Some studies performed in animals and very few obser-
vational studies in humans suggest that sildenafil modu-
lates immune system function. Both PDE5 and OPN are 
expressed in immune cells. Nevertheless, sildenafil’s effects 
on healthy humans lymphocytes were not assessed. There-
fore, the aim of this study was to investigate the ability of 
sildenafil to regulate OPN expression in peripheral blood 
mononuclear cells (PBMCs) from healthy men.
Materials and Methods
PBMCs Isolation
Ten milliliters of venous blood was collected from 16 
healthy blood donors (men). Informed consent was 
obtained from all individual participants included in 
the study. PBMCs isolation was performed within 2  h of 
withdrawal of blood. Blood samples were taken into pre-
servative-free heparin (20  units/ml) tubes, and PBMCs 
were isolated by centrifugation on Histopaque-1077 
(Sigma Aldrich, Germany) of the blood diluted 1:1 with 
0.9% sodium chloride (0.9% NaCl, Fresenius Kabi, Ger-
many). PBMCs pellet was resuspended in Parker medium 
(Biomed, Poland) supplemented with 2  mM l-glutamine 
(Sigma Aldrich, Germany), 0.1 mg/ml gentamycin (KRKA, 
Slovenia), β-mercaptoethanol (Sigma Aldrich, Germany), 
0.23% Hepes (Sigma Aldrich, Germany) and 10% fetal 
bovine serum (FBS; Gibco, USA).
Sildenafil Solution Preparation
Sildenafil citrate salt (Sigma Aldrich, Germany) was dis-
solved in 0.9% sodium chloride (0.9% NaCl, Fresenius 
Kabi, Germany) to initial concentrations of 100 and 10 µg/
ml.
Co‑culture of PBMCs with Sildenafil and Stimulation 
with Phorbol Myristate Acetate Plus Ionomycin
PBMCs were seeded at a density of 1 × 106 cells/well in 
24-well plates (Greiner  CELLSTAR®). Sildenafil solutions 
were added to PBMCs cultures to final concentrations of 
400 ng/ml (0.6 µM) or 4 µg/ml (6 µM). Four hundred ng/
ml is a serum level of sildenafil after single oral adminis-
tration (Nichols et al. 2002). Four µg/ml is tenfold higher. 
Drug concentrations have been selected on the basis of 
the near therapy doses, according to their pharmacokinet-
ics (Cmax and area under the time-concentration curve). 
Control cultures contained an equivalent volume of 0.9% 
NaCl. PBMCs were cultured for 20 h at 37 °C in a sterile 
environment with 5%  CO2 and humidified atmosphere. 
After the incubation period, phorbol myristate acetate 
(PMA) plus ionomycin (Sigma Aldrich, Germany; 50 ng/
ml and 1  µg/ml, respectively) was added to well with 
PBMCs and two with PBMCs treated with sildenafil. One 
well with PBMCs and two with PBMCs and sildenafil were 
not stimulated. Next, PBMCs were incubated at 37 °C in a 
sterile environment with 5%  CO2 and humidified atmos-
phere for 4 h. After the incubation period, culture superna-
tants were collected and stored at −80 °C for measurement 
of OPN concentration by enzyme-linked immunosorbent 
assay (ELISA). PBMCs pellets were lysed with 350 µl of 
RA1 lysis buffer (NucleoSpin RNA, Macherey&Nagel, 
Germany) containing 3.5  µl of β-mercaptoethanol (Sigma 
Aldrich, Germany) and stored at −80 °C for RNA isolation.
Measurement of OPN Concentration by ELISA
To detect OPN secretion in PBMCs supernatants in 
response to sildenafil, we measured the concentration of 
this protein by ELISA according to the manufacturer’s 
instructions (Human OPN Elisa Kit, Sunred Biological 
Technology, China) in duplicates. Chromate 4300 Micro-
plate Reader was used for reading at 450 nm. The results 
were expressed in ng/ml.
RNA Extraction, Reverse Transcription and Real‑Time 
PCR
Total RNA was extracted from PBMCs with the Nucle-
oSpin RNA kit (Macherey&Nagel, Germany) in accord-
ance with the instructions of the supplier. Total RNA was 
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eluted in a 50-µl volume of RNase-free water. RNA con-
centration was analyzed by NanoDrop spectrophotometer 
(ND-1000 Spectrophotometer, NanoDrop Technologies, 
Inc, USA). 0.1  μg of total RNA was reverse transcribed 
into cDNA using a commercially available High Capac-
ity cDNA Reverse Transcription Kit (Applied Biosystems, 
USA) according to the manufacturer’s instruction. Detec-
tion of mRNA level in the samples was performed using 
real-time PCR (RT-PCR) on ABI Prism 7500 Sequence 
Detector (Applied Biosystems, USA). The analysis of OPN 
gene expression was performed using a human commer-
cial available assay Hs00959010_m1 (Applied Biosystems, 
USA). Fluorescence intensities were analyzed using the 
manufacturer’s software (7500 Software v2.05) and relative 
amounts were obtained using the 2−∆∆Ct method and nor-
malized for the glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH).
Cell Viability Assay
PBMCs were collected by centrifugation and stained with 
0.4% trypan blue. Number of total and dead cells was 
counted using a hemocytometer. Values were expressed as 
a percentage of control culture (100%).
Statistical Analysis
All analyses were performed with Statistica version 12.5. 
Results were analyzed using Student’s t test. Data from 
ELISA and RT-PCR were presented as means ± standard 
deviations (SD). A probability value of p < 0.05 with a 95% 
confidence interval was considered to indicate a statisti-
cally significant difference. All ELISA and RT-PCR analy-
ses were performed in duplicates.
Results
To investigate the ability of sildenafil to regulate 
OPN expression in human PBMCs, non-stimulated or 
PMA + ionomycin-stimulated cells were cultured in the 
absence or presence of sildenafil at concentrations of 
400 ng/ml and 4 µg/ml.
Cell Viability
Cell viability was assessed by trypan blue staining. Silde-
nafil had no effect on the viability of PBMCs (percent-
age of viable cells 98 ± 1.3%; range: 96–99%) in both 
concentrations.
Supernatant OPN Concentrations
Concentrations of OPN in PBMCs supernatants among the 
different experimental conditions are shown in Fig. 1.
The analysis of OPN concentration in PBMCs super-
natants revealed that PMA stimulation resulted in a sig-
nificant increase of OPN production (p < 0.001). We found 
that sildenafil at both concentrations (4 µg/ml and 400 ng/
ml) significantly decreased PMA-induced OPN secretion 
(p < 0.05). Moreover, sildenafil at a concentration of 4 µg/
ml significantly decreased the OPN secretion more than at 
a concentration of 400 ng/ml (p < 0.05). However, sildena-
fil had no significant effects on OPN protein secretion by 
PBMCs which were not stimulated with PMA plus iono-
mycin (Fig. 1).
mRNA OPN Expression by PBMCs
The analysis of OPN gene expression revealed that PBMCs 
stimulation with PMA plus ionomycin resulted in a sig-
nificant upregulation of OPN compared to unstimulated 
PBMCs (p < 0.001). Sildenafil at a concentration of 4 µg/
ml significantly decreased PMA-induced OPN gene expres-
sion (p < 0.05). In addition, we observed that sildenafil had 
no effectt on OPN gene expression in unstimulated PBMCs 
(Table 1; Fig. 2).
Discussion
During the last decade it has become clear that inflamma-
tion is an important contributor to the development of mul-
tiple disorders. Thus, immunomodulatory therapy is benefi-
cial for many diseases.
OPN is expressed by a wide variety of cell types, includ-
ing immune system cells. OPN is a pleiotropic protein and 
its functions are linked to various physiological functions 
and pathological conditions.
Several studies in animal models have shown that silde-
nafil, a selective PDE5 inhibitor, exerts anti-inflammatory 
effects but some studies gave inconclusive results.
The study of Pifarre et  al. (2011) demonstrated that 
sildenafil decreased  CD3+ leukocyte infiltration in the 
spinal cord in a mouse model of multiple sclerosis and 
increased forkhead box p3-expressing T regulatory cells 
(Foxp3 Tregs). However, this drug did not affect production 
of Th1/Th2 cytokines in mice splenocytes. In another study, 
Yildirim et al. (2010) evaluated the influence of sildenafil 
on tumor necrosis factor (TNF)-α and IL-1β production in 
rats with induced lung fibrosis. The group demonstrated 
that sildenafil administration decreased serum levels of 
these cytokines. A strong anti-inflammatory effect of silde-
nafil was demonstrated in another study conducted in mice 
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(Nunes et al. 2012). It revealed that sildenafil can decrease 
the levels of TNF-α, interferon (IFN)-γ, IL-2 and IL-1β 
in animal model of multiple sclerosis. In another study, 
Pifarré et al. (2014) observed that sildenafil downregulates 
Th1/Th2/Th17 responses (IL-2, IL-4, IFN-γ) and upregu-
lates Tregs. However, these results were not confirmed by 
studies of Clayton et  al. (2004) and Tsai et  al. (2006). In 
these investigations, sildenafil did not inhibit TNF-α, IL-4 
Fig. 1  Effects of sildenafil on osteopontin (OPN) produc-
tion in peripheral blood mononuclear cells (PBMCs). Experi-
ments were performed on phorbol myristate acetate (PMA) plus 
ionomycin-stimulated and unstimulated PBMCs after incuba-
tion with sildenafil (at concentrations of 400  ng/ml and 4  µg/
ml). The level of OPN in supernatants was measured by enzyme-
linked immunosorbent assay (ELISA, mean ± SD). Statistically 
significant differences were considered when p<0.05 for Stu-
dent’s t test on 16 PBMCs samples. **p < 0.001 (unstimulated 
PBMCs vs. PMA + ionomycin-stimulated PBMCs with and with-
out sildenafil incubation). *p < 0.05 (PBMCs + PMA + iono-
mycin vs. PBMCs + PMA + ionomycin + sildenafil 400  ng/ml, 
PBMCs + PMA + ionomycin vs. PBMCs + PMA + ionomycin + silde-
nafil 4 µg/ml and PBMCs + PMA + ionomycin + sildenafil 400 ng/ml 
vs. PBMCs + PMA + ionomycin + sildenafil 4 µg/ml)
Table 1  Effects of sildenafil on 
osteopontin gene expression in 
PBMCs
ΔCt values (mean ± SD) for osteopontin (OPN) in peripheral blood mononuclear cells (PBMCs) deter-
mined by RT-PCR after incubation with sildenafil and with and without stimulation with phorbol myristate 
acetate (PMA) plus ionomycin. Statistically significant differences were considered when p˂0.05 for Stu-
dent’s t test on 16 PBMCs samples
NS not significant
*PBMCs + sildenafil 400 ng/ml and PBMCs + sildenafil 4 µg/ml vs. PBMCs
**PBMCs + PMA + ionomycin + sildenafil 4 µg/ml vs. PBMCs + PMA + ionomycin
ΔCt ± SD p
PBMCs 5.403 ± 1.518
PBMCs + sildenafil 400 ng/ml 5.379 ± 1.008 NS*
PBMCs + sildenafil 4 µg/ml 5.016 ± 1.456 NS*
PBMCs + PMA + ionomycin –2.207 ± 0.951
PBMCs + PMA + ionomycin + sildenafil 400 ng/ml –1.689 ± 0.744 0.06
PBMCs + PMA + ionomycin + sildenafil 4 µg/ml –1.187 ± 1.267 <0.05**
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and IL-5 in mice. Karakhanova et  al. (2013) evaluated 
the influence of sildenafil on T lymphocytes in mice. The 
authors observed that sildenafil treatment has a tendency 
to decrease the percentage of  CD4+ and to increase  CD8+ 
T cells in male mice. Moreover, sildenafil decreased the 
serum level of IL-6 in healthy mice (Karakhanova et  al. 
2013). In addition, it has been observed that application of 
sildenafil led to a prolonged survival of pancreatic ductal 
adenocarcinoma (PDAC)-bearing mice, which was due to 
the decrease in myeloid-derived suppressor cells frequen-
cies and in the systemic vascular endothelial growth factor 
level. This led to a recovery of T lymphocyte functions and 
an increase in the frequency of  CD4+ T cells in tumors and 
IFN-γ level in serum of PDAC-bearing mice (Karakhanova 
et al. 2015). In another study conducted in animal model, 
Schäfer et  al. (2009) invastigated the effects of sildenafil 
on right ventricular remodeling in rats subjected to mono-
crotaline-induced pulmonary hypertension. The authors 
observed that sildenafil reduces pulmonary pressure and 
downregulates markers of hypertrophy and remodeling in 
the right ventricle, including OPN. A promising role for 
this PDE5 inhibitor in the modulation of inflammatory pro-
cesses has also been reported in renal damage in a study of 
Jeong et al. (2009). The authors observed that in streptozo-
tocin-induced diabetic rats sildenafil treatment may attenu-
ate renal damage by ameliorating oxidative and inflamma-
tory injuries. Sildenafil-treated rats had significantly lower 
monocyte chemotactic protein-1 (MCP-1) RNA expression. 
In another study in diabetic mice, Venneri et  al. (2015) 
demonstrated that circulating renal and cardiac Tie2-
expressing monocytes (TEMs) are defective in chronic 
hyperglycemia and that sildenafil normalized their levels 
by facilitating the shift from classic (M1-like) to alternative 
(M2-like)/TEM macrophage polarization. These authors 
suggested that restoration of tissue TEMs with sildenafil 
could represent an additional pharmacological tool to pre-
vent end-organ diabetic complications.
Moreover, several studies have shown that sildenafil 
exerts immunomodulatory effects in humans. The aim of 
a study conducted by Pifarré et al. (2014) was to evaluate 
sildenafil’s effect on healthy human T effector cells (Teffs). 
The authors observed that sildenafil significantly decreased 
IL-2 in Teffs supernatants but changes in IL-4 and IL-13 
were not observed. In another study, Di Luigi et  al. 
(2016) evaluated the effects of sildenafil on level of Th1 
chemokine CXCL10 in human cardiomyocytes. The group 
observed that sildenafil significantly decreased CXCL10 in 
human cardiomyocytes and decreased circulating CXCL10 
in patients with diabetic cardiomyopathy. In light of those 
evidences the authors speculated that sildenafil could be a 
new tool to control CXCL10-associated inflammation in 
diabetic cardiomyopathy. The aim of another study con-
ducted by Vlachopoulos et al. (2015) was to investigate the 
effect of sildenafil on circulating pro-inflammatory markers 
in ED patients. The authors reported that administration of 
sildenafil reduced production of fibrinogen, high-sensitivity 
C-reactive protein, high-sensitivity IL-6 and TNF-α. This 
study demonstrated for the first time the effect of sildena-
fil administration on pro-inflammatory markers in men 
with ED. Several studies conducted in patients with type 
2 diabetes demonstrated that chronic treatment with silde-
nafil is associated with cardioprotection and reduced lev-
els of circulating inflammatory cytokines. Gianetta et  al. 
(2012, 2014) observed that sildenafil reduced concentra-
tion of MCP-1 and transforming growth factor-β in patients 
with type 2 diabetes. Similar study conducted in diabetic 
patients by Aversa et al. (2008) demonstrated that sildenafil 
administration reduced markers of vascular inflammation, 
including the level of IL-6.
The present study evaluated the effects of sildenafil on 
OPN production in PBMCs from healthy men. Our study 
demonstrated that sildenafil downregulates OPN gene 
expression and OPN protein production in PMA-stimulated 
PBMCs within no effect on unstimulated cells. To the best 
of our knowledge, this is the first report describing such 
effects of this PDE5 inhibitor in healthy humans.
PMA activates  Ca2+/phospholipid-dependent enzyme 
protein kinases C (PKCs). Activated PKCs regulate mul-
tiple physiological processes and activate the NF-κB 
transcription factors (New and Wong 2007). We could 
Fig. 2  Relative osteopontin (OPN) expression in peripheral blood 
mononuclear cells (PBMCs) determined by RT-PCR (mean). Experi-
ments were performed on phorbol myristate acetate (PMA) plus ion-
omycin-stimulated and unstimulated PBMCs after incubation with 
sildenafil (at a concentrations of 400 ng/ml and 4 µg/ml)
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speculate that in PBMCs, high levels of cGMP induced 
by sildenafil reduce the concentration of  Ca2+ ions in 
cytosol, leading to a reduction of PKC and consequently 
NF-κB activity which contributes to a decreased OPN 
production. Significantly reduced concentration of OPN 
in supernatants from unstimulated PBMCs was not 
observed probably because the sensitivity of the OPN 
ELISA kit was insufficient to discern the difference when 
the level is close to the lower end of detection limit.
OPN is a pleiotropic protein which is involved in mul-
tiple physiological and pathological conditions. Sildena-
fil  (Viagra® Pfizer) is a relatively commonly prescribed 
drug, especially for elderly patients whose immune 
system may weaken as a natural result of aging. It may 
be the cause of immunologic complications. It is very 
important to know whether sildenafil can induce immu-
nological changes in healthy organisms. It may reduce 
the risk of immune system side effects and possible drug-
to-drug interactions.
In conclusion, in healthy men PBMCs, sildenafil down-
regulates OPN production and gene expression. Despite 
accumulating evidence for the immunomodulatory effects 
of sildenafil on human immune system cells, further stud-
ies are needed to determine if this drug affects the level of 
cGMP and NF-ĸB in PBMCs. In addition, it is needed to 
evaluate sildenafil’s effect in PBMCs from patients with 
elevated OPN levels (type 2 diabetes, cardiovascular dis-
eases, liver diseases, some autoimmune diseases, etc.).
Acknowledgements This research was supported by the intramural 
grant of Medical University of Warsaw (1MG/PM11/15).
Compliance with ethical standards 
All procedures performed in studies involving human participants 
were in accordance with the ethical standards of the institutional and/
or national research committee and with the 1964 Helsinki declaration 
and its later amendments or comparable ethical standards.
Conflict of interest The authors declare that they have no conflict 
of interest.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
Afify MF, Mohamed GB, El-Maboud MA et al (2009) Plasma con-
centration of osteopontin (OPN) in children with systemic lupus 
erythematosus: relationship with disease activity. Open Autoim-
mun J 1:59–63
Ashkar S, Weber GF, Panoutsakopoulou V et al (2000) Eta-1 (osteo-
pontin): an early component of type-1 (cell-mediated) immunity. 
Science 287:860–864
Aversa A, Vitale C, Volterrani M et al (2008) Chronic administration 
of Sildenafil improves markers of endothelial function in men 
with Type 2 diabetes. Diabet Med 25:37–44
Boswell-Smith V, Spina D, Page CP (2006) Phosphodiesterase inhibi-
tors. Br J Pharmacol 147(suppl 1):S252–S257
Brown A (2012) Osteopontin: a key link between immunity, inflam-
mation and the central nervous system. Transl Neurosci 
3:288–293
Cantor H (1995) The role of Eta-1/osteopontin in the pathogenesis of 
immunological disorders. Ann N Y Acad Sci 760:143–150
Cao DX, Li ZJ, Jiang XO et al (2012) Osteopontin as potential bio-
marker and therapeutic target in gastric and liver cancers. World 
J Gastroenterol 18:3923–3930
Carecchio M, Comi C (2011) The role of osteopontin in neurodegen-
erative diseases. J Alzheimers Dis 25:179–185
Chrysant SG, Chrysant GS (2012) The pleiotropic effects of phos-
phodiesterase 5 inhibitors on function and safety in patients 
with cardiovascular disease and hypertension. J Clin Hypertens 
14:644–649
Clayton RA, Dick CAJ, Mackenzie A et al (2004) The effect of selec-
tive phosphodiesterase inhibitors, alone and in combination, on a 
murine model of allergic asthma. Respir Res 5:4
Denhardt DT, Guo X (1993) Osteopontin: a protein with the diverse 
functions. FASEB J 7:1475–1482
Denhardt DT, Noda M (1998) Osteopontin expression and function: 
role in bone remodeling. J Cell Biochem Suppl 30–31:92–102
Di Luigi L, Corinaldesi C, Colletti M et  al (2016) Phosphodiester-
ase type 5 inhibitor sildenafil decreases the proinflammatory 
chemokine CXCL10 in human cardiomyocytes and in subjects 
with diabetic cardiomyopathy. Inflammation 39:1238–1252
Fisher LW, Torchia DA, Fohr B et  al (2001) Flexible structures of 
SIBLING proteins, bone sialoprotein, and osteopontin. Biochem 
Biophys Res Commun 280:460–465
Frenzel DF, Weiss JM (2011) Osteopontin and allergic disease: patho-
physiology and implications for diagnostics and therapy. Expert 
Rev Clin Immunol 7:93–109
Giannetta E, Isidori AM, Galea N et al (2012) Chronic inhibition of 
cGMP phosphodiesterase 5 A improves diabetic cardiomyo-
pathy: a randomized, controlled clinical trial using magnetic 
resonance imaging with myocardial tagging. Circulation 
125:2323–2333
Giannetta E, Feola T, Gianfrilli D et  al (2014) Is chronic inhibition 
of phosphodiesterase type 5 cardioprotective and safe? A meta-
analysis of randomized controlled trials. BMC Med 12:185
Glas J, Seiderer J, Bayrle C et  al (2011) The role of osteopontin 
(OPN/SPP1) haplotypes in the susceptibility to Crohn’s disease. 
PLoS One 6:e29309
Harris VK, Sadiq SA (2009) Disease biomarkers in multiple sclerosis: 
potential for use in therapeutic decision making. Mol Diagn Ther 
13:225–244
Jeong KH, Lee TW, Ihm CG et al (2009) Effects of sildenafil on oxi-
dative and inflammatory injuries of the kidney in streptozotocin-
induced diabetic rats. Am J Nephrol 29:274–282
Karakhanova S, Yang Y, Link J et al (2013) Gender-specific immuno-
logical effects of the phosphodiesterase 5 inhibitor sildenafil in 
healthy mice. Mol Immunol 56:649–659
Karakhanova S, Link J, Heinrich M et al (2015) Characterization of 
myeloid leukocytes and soluble mediators in pancreatic cancer: 
importance of myeloid-derived suppressor cells. Oncoimmunol-
ogy 4:e998519
Konno S, Kurokawa M, Uede T et  al (2011) Role of osteopontin, a 
multifunctional protein, in allergy and asthma. Clin Exp Allergy 
41:1360–1366
Arch. Immunol. Ther. Exp. 
1 3
Mishima R, Takeshima F, Sawai T et  al (2007) High plasma osteo-
pontin levels in patients with inflammatory bowel disease. J Clin 
Gastroenterol 41:167–172
Murugaiyan G, Mittal A, Weiner HL (2008) Increased osteopon-
tin expression in dendritic cells amplifies IL-17 production by 
CD4+ T cells in experimental autoimmune encephalomyelitis 
and in multiple sclerosis. J Immunol 181:7480–7488
New DC, Wong YH (2007) Molecular mechanisms mediating the G 
protein-coupled receptor regulation of cell cycle progression. J 
Mol Signal 2:2
Nichols DJ, Muirhead GJ, Harness JA (2002) Pharmacokinetics of 
sildenafil after single oral doses in healthy male subjects: abso-
lute bioavailability, food effects and dose proportionality. Br J 
Clin Pharmacol 53(Suppl 1):5S–12S
Nunes AKS, Raposo C, Luna RL et  al (2012) Sildenafil  (Viagra®) 
down regulates cytokines and prevents demyelination in a cupri-
zone-induced MS mouse model. Cytokine 60:540–551
Pifarre P, Prado J, Baltrons MA et al (2011) Sildenafil (Viagra) ame-
liorates clinical symptoms and neuropathology in a mouse model 
of multiple sclerosis. Acta Neuropathol 121:499–508
Pifarré P, Gutierrez-Mecinas M, Prado J et al (2014) Phosphodiester-
ase 5 inhibition at disease onset prevents experimental autoim-
mune encephalomyelitis progression through immunoregulatory 
and neuroprotective actions. Exp Neurol 251:58–71
Ramaiah SK, Rittling S (2008) Pathophysiological role of osteopon-
tin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 
103:4–13
Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in 
cell signaling and cancer progression. Trends Cell Biol 16:79–87
Schäfer S, Ellinghaus P, Janssen W et al (2009) Chronic inhibition of 
phosphodiesterase 5 does not prevent pressure-overload-induced 
right-ventricular remodelling. Cardiovasc Res 82:30–39
Shinohara ML, Lu L, Bu J et  al (2006) Osteopontin expression is 
essential for interferon-alpha production by plasmacytoid den-
dritic cells. Nat Immunol 7:498–506
Singh M, Ananthula S, Milhorn DM et al (2007) Osteopontin: a novel 
inflammatory mediator of cardiovascular disease. Front Biosci 
12:214–221
Sodek J, Ganss B, McKee MD (2000) Osteopontin. Crit Rev Oral 
Biol Med 11:279–303
Szczypka M, Ploch S, Obmińska-Mrukowicz B (2012) Modulation 
of Th1/Th2 cytokine production by selective and nonselective 
phosphodiesterase inhibitors administered to mice. Pharmacol 
Rep 64:179–184
Tsai BM, Turrentine MW, Sheridan BC et  al (2006) Differential 
effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary 
vasoconstriction and pulmonary artery cytokine expression. Ann 
Thorac Surg 81:272–278
Uede T (2011) Osteopontin, intrinsic tissue regulator of intractable 
inflammatory diseases. Pathol Int 61:265–280
Venneri MA, Giannetta E, Panio G et  al (2015) Chronic inhibi-
tion of PDE5 limits pro-inflammatory monocyte-macrophage 
polarization in streptozotocin-induced diabetic mice. PLoS One 
10:e0126580
Vlachopoulos C, Ioakeimidis N, Rokkas K et al (2015) Acute effect 
of sildenafil on inflammatory markers/mediators in patients with 
vasculogenic erectile dysfunction. Int J Cardiol 182:98–101
Wai PY, Kuo PC (2004) The role of osteopontin in tumor metastasis. J 
Surg Res 121:228–241
Wang KX, Denhardt DT (2008) Osteopontin: role in immune 
regulation and stress response. Cytokine Growth Factor Rev 
19:333–345
Yildirim A, Ersoy Y, Ercan F et al (2010) Phosphodiesterase-5 inhi-
bition by sildenafil citrate in a rat model of bleomycin-induced 
lung fibrosis. Pulm Pharmacol Ther 23:215–221
Zandman-Goddard G, Shoenfeld Y (2003) SLE and infections. Clin 
Rev Allergy Immunol 25:29–40
